- Home
- URG vs ACIU Comparison
URG vs ACIU Comparison
Compare URG & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URG
- ACIU
- Stock Information
- Founded
- URG 2004
- ACIU 2003
- Country
- URG United States
- ACIU Switzerland
- Employees
- URG N/A
- ACIU N/A
- Industry
- URG Precious Metals
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- URG Basic Materials
- ACIU Health Care
- Exchange
- URG Nasdaq
- ACIU Nasdaq
- Market Cap
- URG 342.2M
- ACIU 305.7M
- IPO Year
- URG N/A
- ACIU 2016
- Fundamental
- Price
- URG $1.20
- ACIU $3.27
- Analyst Decision
- URG Strong Buy
- ACIU Strong Buy
- Analyst Count
- URG 2
- ACIU 2
- Target Price
- URG $2.45
- ACIU $12.00
- AVG Volume (30 Days)
- URG 3.4M
- ACIU 86.5K
- Earning Date
- URG 11-06-2024
- ACIU 11-05-2024
- Dividend Yield
- URG N/A
- ACIU N/A
- EPS Growth
- URG N/A
- ACIU N/A
- EPS
- URG N/A
- ACIU N/A
- Revenue
- URG $16,494,000.00
- ACIU $48,505,404.00
- Revenue This Year
- URG $89.01
- ACIU N/A
- Revenue Next Year
- URG $81.36
- ACIU $938.44
- P/E Ratio
- URG N/A
- ACIU N/A
- Revenue Growth
- URG 34.78
- ACIU 4097200.00
- 52 Week Low
- URG $0.96
- ACIU $2.25
- 52 Week High
- URG $2.01
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- URG 44.63
- ACIU 54.36
- Support Level
- URG $1.25
- ACIU $2.80
- Resistance Level
- URG $1.35
- ACIU $3.12
- Average True Range (ATR)
- URG 0.06
- ACIU 0.17
- MACD
- URG -0.01
- ACIU 0.03
- Stochastic Oscillator
- URG 11.11
- ACIU 97.92
About URG Ur Energy Inc (Canada)
Ur-Energy Inc is y is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.